Valuation: AbbVie Inc.

Market Cap 471B 418B 391B 355B 670B 45,430B 675B 4,702B 1,829B 23,176B 1,769B 1,731B 74,504B P/E 2026 *
37.7x
P/E 2027 * 25.2x
Enterprise Value 533B 473B 443B 401B 758B 51,388B 764B 5,319B 2,069B 26,215B 2,001B 1,958B 84,276B EV / Sales 2026 *
7.89x
EV / Sales 2027 * 7.13x
Free-Float
95.71%
Yield 2026 *
2.6%
Yield 2027 * 2.7%
1 day+0.35%
1 week+1.17%
Current month+1.84%
1 month+3.90%
3 months+4.28%
6 months+27.91%
Current year+14.29%
1 week 36.04
Extreme 36.04
37.19
1 month 34.38
Extreme 34.38
37.19
Current year 26.89
Extreme 26.89
37.19
1 year 26.89
Extreme 26.89
37.19
3 years 19.83
Extreme 19.83
37.19
5 years 19.45
Extreme 19.45
37.19
10 years 19.45
Extreme 19.45
37.19
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%+1.17% - - 471B
+1.26%-2.29%+36.97%+104.79% 1,032B
+0.73%-4.78%+35.41%+61.62% 614B
+0.35%+1.29%+15.86%+79.90% 471B
+1.72%-4.92%+59.84%+36.64% 350B
+1.01%+1.20%+22.46%+40.84% 337B
+0.94%-1.40%+12.48%+34.21% 268B
+0.01%-2.80%-6.60%+9.95% 246B
-0.09%-4.97%+36.88%+50.52% 218B
-0.28%-4.66%+26.99%+92.98% 179B
Average +0.24%-3.39%+26.70%+56.83% 412.76B
Weighted average by Cap. +0.30%-3.18%+29.73%+67.14%

Financials

2026 *2027 *
Net sales 67.6B 60.01B 56.16B 50.9B 96.13B 6,517B 96.82B 674B 262B 3,324B 254B 248B 10,687B 73.5B 65.24B 61.05B 55.34B 105B 7,085B 105B 733B 285B 3,614B 276B 270B 11,619B
Net income 13.93B 12.36B 11.57B 10.49B 19.81B 1,343B 19.95B 139B 54.05B 685B 52.28B 51.16B 2,202B 19.16B 17.01B 15.92B 14.43B 27.24B 1,847B 27.44B 191B 74.35B 942B 71.91B 70.37B 3,029B
Net Debt 61.81B 54.87B 51.35B 46.54B 87.89B 5,958B 88.53B 617B 240B 3,040B 232B 227B 9,771B 53.09B 47.13B 44.1B 39.98B 75.5B 5,118B 76.04B 530B 206B 2,611B 199B 195B 8,393B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
06/10/26 CA$37.03 +0.35% 6,743
05/10/26 CA$36.90 +0.79% 7,298
02/10/26 CA$36.61 +1.44% 4,274
01/10/26 CA$36.09 -0.74% 4,629
30/09/26 CA$36.36 -0.66% 686
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
266.69USD
Average target price
280.29USD
Spread / Average Target
+5.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbbVie Inc.